Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.

Autor: Stepanishyna Y; Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine.; Department of Hematology, Jules Bordet Institute, Brussels, Belgium., Manni M; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy., Civallero M; Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy., Shokun N; Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine., Skrypets T; Hematology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Burtna A; Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine., Shapovalenko N; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Tytorenko I; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Aleksyk O; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Pastushenko Y; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Gubareva H; Department of medical statistics and national cancer register, National Cancer Institute, Kyiv, Ukraine., Moiseienko K; Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine., Kadnikova T; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Rudyuk T; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Filonenko K; Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland., Martynchyk A; Department of Hematology, Austin Health, Melbourne, Australia., Novosad O; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Galli GR; Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy., Kryachok I; Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine., Federico M; Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1757-1761. Date of Electronic Publication: 2024 Feb 23.
DOI: 10.1111/bjh.19352
Abstrakt: We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019-2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B-cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL), 16 (2.9%) of mantle cell lymphoma (MCL) and 20 (3.5%) of peripheral T-cell lymphoma (PTCL). After a median follow-up of 30.1 months (95% CI: 28.8-31.3), the 3-year overall survival rates were 95%, 83%, 86%, 100%, 61% and 42% for HL, DLBCL, CLL, FL, MCL and PTCL respectively. These data offer valuable information on the curability of lymphoma patients in Ukraine, in a real-world setting.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: